Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumab.

Ikko Tomisaki,Mirii Harada,Shigeru Sakano,Michikazu Terado,Ryoichi Hamasuna,Shuji Harada,Hiroomi Matsumoto,Soichiro Akasaka,Yujiro Nagata,Akinori Minato,Ken‐ichi Harada,Naohiro Fujimoto

International journal of urology : official journal of the Japanese Urological Association（2023）

引用 1|浏览9

暂无评分

摘要

The use of a concomitant proton pump inhibitor use had no impact on oncological outcomes in patients with advanced urothelial carcinoma treated with paclitaxel-gemcitabine therapy, different from those treated with pembrolizumab.

查看译文

关键词

chemotherapy,immune checkpoint inhibitor,paclitaxel-gemcitabine,pembrolizumab,proton pump inhibitor,urothelial carcinoma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要